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Objective measures of disease activity have at-
tracted considerable interest within dermatology 
because of their capacity to evaluate disease severity 
through a validated means, to monitor the trajectory 
of a patient’s disease and as standardised outcome 
measures in clinical trials (1). Two disease-specific in-
struments exist for measuring the extent of autoim-
mune bullous diseases: the Autoimmune Bullous Skin 
Disorder Intensity Score (ABSIS) (2), and the Pemphi-
gus Disease Area Index (PDAI) (3). All patients attend-
ing specialised Bullous Clinics at our institution have 
a standardised profile recorded at each presentation 
including ABSIS and PDAI scores, medication dosages 
and quality of life (QOL) scores, such as the Dermatol-
ogy Life Quality Index (4), allowing us to map their 
disease longitudinally and evaluate the quality of 
care. This information has traditionally been recorded 
in hardcopy with the patient and clinician completing 
a series of forms. This imposes a significant adminis-
trative burden and extrapolating the data into useful 
information then necessitated going through each 
form by hand, which was impractical. To improve the 
efficiency of this process, our institution has devel-
oped a specialised Excel® spreadsheet, which records 
a series of clinical variables at each presentation. Each 
column represents a data field on the forms for the 
ABSIS, PDAI and QOL instruments as well as medica-
tion dosages. Many of the instruments require arith-
metic calculations (for example, scoring the ABSIS 
requires multiplying affected body surface area by an 
index dependent on the severity of lesions) and we 
have programmed the spreadsheet to perform this 
automatically, making the process appreciably faster. 
Another major advantage of the spreadsheet is that 
it facilitates data extraction. Using the graph func-
tion of the spreadsheet to map the clinical course of 
a patient, one can instantly appreciate how their dis-
ease has evolved over time across a range of param-
Figure 1a. Disease activity scores
Figure 1b. Immunosuppresion
Figure 1c. Quality of lite scores
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eters including disease activity, QOL and the need 
for immunosuppression (Fig. 1). We have included a 
number of features to assist new users of the spread-
sheet such as explanatory ‘pop-ups’, which provide 
information explaining the meaning of the data field 
when the patient clicks on a particular cell. We have 
also placed restrictions on the range of values avail-
able to particular data fields because as the ABSIS and 
PDAI scoring systems can be complex to use for those 
unaccustomed to the instruments, by placing limits 
on data fields this helps guide users how to score pa-
tients accurately but also preventing accidental input 
of invalid data. The template we have designed is 
flexible enough to allow users to add other variables 
they feel may warrant inclusion and delete variables 
they may not assess during routine clinical review. 
The spreadsheet built by our group is practical for 
routine clinical use and is a useful tool for longitudi-
nal monitoring of disease activity in bullous patients. 
It possesses a number of advantages over recording 
clinical data by hand, namely, its speed, capacity for 
automated calculation and its ease of data extrapola-
tion, and for these reasons similar spreadsheets could 
be devised to record routine clinical data in other set-
tings (5). 
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